According to Jeff Jacob, CEO of Cancer Prevention Pharmaceuticals, Inc. and a C-Path board member who headed the CEO search process, “With the creation of C-Path as a public/private partnership model, Dr. Woosley forever changed the way scientists share information and navigate the drug development process. After an extensive search, we are thrilled that Dr. Compton will bring her internationally recognized expertise in molecular medicine to further C-Path’s mission and impact. She is the type of dynamic leader that will ensure C-Path continues to evolve as a global leader in redefining the way we treat and cure diseases.”
Most recently, Dr. Compton served as the Director of the Office of Biorepositories and Biospecimen Research (OBBR) and the Executive Director of the Cancer Human Biobank (caHUB) project at the National Cancer Institute (NCI) at the National Institutes of Health (NIH).Dr. Compton is an internationally respected scientist with extensive experience in the areas of translational science and personalized medicine.
She received her MD and PhD degrees from Harvard Medical School and the Harvard Graduate School of Arts and Sciences. She trained in Pathology at Harvard’s Brigham and Women’s Hospital and is boarded in both Anatomic Pathology and Clinical Pathology.
“Dr. Compton is a leader who is well known for her innovative ideas and collaborative style,” said Margaret A. Hamburg, M.D., Commissioner of the U.S. Food and Drug Administration. “As she works to fulfill the Critical Path mission to advance the science that will accelerate medical product development, we very much look forward to working together on these issues that are so important to public health.”
In her new role, Dr. Compton joins the ranks of an already strong bioscience/biomedical culture in Arizona. “C-Path is an exceptional Arizona organization, and Dr. Compton is a scientist of the highest caliber,” said Governor Jan Brewer. “I am confident that Dr. Compton, through her leadership of C-Path, will work to expand key alliances and collaborative relationships so that Arizona bioscience continues to thrive.”
According to Mara Aspinall, President of Ventana Medical Systems, Inc., a global leader in medical diagnostics based in Tucson, “Innovation occurs when passionate scientists from diverse disciplines collaborate on important medical problems. C-Path provides an ideal environment for this type of collaboration. Dr. Compton will enable C-Path to continue to provide leadership in accelerating the development of new diagnostics and therapies.”
ABOUT CRITICAL PATH INSTITUTE (C-PATH): An independent, non-profit organization established in 2005 with public and private philanthropic support from the Arizona community, Science Foundation Arizona (SFAz), and the U.S. Food and Drug Administration (FDA), C-Path is committed to improving health and saving lives by accelerating the development of safe, effective medicines. An international leader in forming collaborations around this mission, C-Path has established global, public-private partnerships that currently include over 1,000 scientists from government regulatory agencies, academia, patient advocacy organizations, and 36 major pharmaceutical companies.C-Path is headquartered in Tucson, Arizona, with offices in Phoenix, Arizona, and Rockville, Maryland. For more information, visit www.c-path.org and follow us on Facebook. Click here to view a video showing why the work of C-Path is essential.
The C-Path Vision: Creating collaborations that advance scientific innovations to improve human health and save lives by accelerating the development of safe, effective medicines.